UNICREDIT BANK/CALL/ELI LILLY & CO/1200/0.1/19.03.25 | Market Closed - Bid/Ask 19:34:53 22/05/2024 BST | Pre-market 07:30:22 | |||
| 1.32 EUR | +33.33% |
|
1.395 | +5.68% |
| Current month | +46.67% | ||
| 1 month | +21.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 1.32 | +33.33% |
| 21/05/24 | 0.99 | -10.81% |
| 20/05/24 | 1.11 | +8.82% |
| 17/05/24 | 1.02 | -6.42% |
| 16/05/24 | 1.09 | -6.03% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 07:34 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD43W8 |
| ISIN | DE000HD43W84 |
| Date issued | 25/03/2024 |
| Strike | 1,200 $ |
| Maturity | 19/03/2025 (301 Days) |
| Parity | 10 : 1 |
| Emission price | 2.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.83 € |
|---|---|
| Lowest since issue | 0.78 € |
| Spread | 0.31 € |
| Spread % | 20.13% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- Warrant
